You have no items in your cart.
-6%
AproVasc 150mg/10mg – Irbesartan Amlodipine, 28 Tablets
Treatment of essential hypertension (high blood pressure)
Active ingredients: Irbesartan 150mg and Amlodipine 10mg
Original price was: ₦11,350.00.₦10,700.00Current price is: ₦10,700.00. — or subscribe and save 10%
Availability: Out of stock
Compare
- Description
- Additional information
- Brand
- How to Use
- Product Details
- Side Effects
- Ingredients
- How to store
- Prescription Product
- Delivery
- Patient Information Leaflet
AproVasc 150mg/10mg – Irbesartan Amlodipine, 28 Tablets
Aprovasc 150mg/10mg is indicated in patients whose blood pressure is not adequately controlled on irbesartan or amlodipine monotherapy.
If you are one of the many people whose blood pressure is not adequately controlled by irbesartan or amlodipine monotherapy, Aprovasc may be the answer you have been looking for. Aprovasc is a unique combination of two proven blood pressure-lowering medications, amlodipine and irbesartan. By lowering blood pressure from both the inside and the outside of blood vessels, Aprovasc is able to effectively control even the most stubborn hypertension. And because it is a once-daily tablet, Aprovasc is easy to take and convenient to fit into your busy schedule. So if you are looking for a new way to get your blood pressure under control, ask your doctor about Aprovasc
AproVasc 150mg/10mg Reviews
After using 150mg/10mg, it’s helpful to let others know about your experience. Reviews of an item help other users know that medicines received have helped the condition it is claimed for, how well the treatment worked or any issues to be aware of. We invite our users to leave a review of both their treatment and of the service provided. Click on the reviews tab to see if there has been feedback on this item.
What is the price of AproVasc 150mg/10mg in Nigeria?
The price of AproVasc 150mg/10mg is N9,700
Where can you buy AproVasc 150mg/10mg In Nigeria?
You can Buy AproVasc 150mg/10mg at Asset Pharmacy Lagos Nigeria, Nigeria’s Largest Online Pharmacy.
AproVasc 150mg/10mg is a prescription drug that legally requires a medical prescription to be dispensed.
To order this product you confirm that you are under the care of your doctor or consultant and have been given permission by them for purchase, fulfillment & use in treatment with their written consent.
You will be required to send Asset Pharmacy your prescription
Asset Pharmacy
1A, Olugbesan Close, Off Adegbeyemi Street, Allen Street, Ikeja, Lagos, Nigeria
Tel 09034553795
https://www.assetpharmacy.com/
https://goo.gl/maps/gYhZUBdP3UP8nrY67
Brand
Aprovasc
How to Use
How to use AproVasc
The recommended dosage of Irbesartan/Amlodipine (Aprovasc) is one tablet per day.
Irbesartan/Amlodipine (Aprovasc) should be administered in patients whose blood pressure is not adequately controlled on monotherapy with irbesartan or amlodipine or for continuation of therapy for patients receiving irbesartan and amlodipine as separate tablets.
Product Details
Product Information of AproVasc
Contraindications
Due to the presence of both irbesartan and amlodipine in the medicinal product, Irbesartan/Amlodipine (Aprovasc) is contraindicated in hypersensitivity to either or both of the active substances or to any of the excipients; hypersensitivity to dihydropyridines; cardiogenic shock, clinically significant aortic stenosis, unstable angina (excluding Prinzmetal’s angina); pregnancy and lactation. (See Warnings and Use in Pregnancy & Lactation.)
Do not co-administer Irbesartan/Amlodipine (Aprovasc) with aliskiren-containing medicines in patients with diabetes or with moderate to severe renal impairment (glomerular filtration rate [GFR] <60 mL/min/1.73 m2). (See Precautions and Interactions.)
Do not co-administer Irbesartan/Amlodipine (Aprovasc) with Angiotensin-Converting Enzyme Inhibitors (ACEIs) in patients with diabetic nephropathy.
Warnings
Hypotension-Volume-Depleted Patients: Irbesartan has been rarely associated with hypotension in hypertensive patients without other comorbid conditions. Symptomatic hypotension, as with ACE inhibitors, may be expected to occur in sodium/volume-depleted patients such as those treated vigorously with diuretics and/or salt restriction, or on hernodialysis. Volume and sodium-depletion should be corrected before initiating therapy with Irbesartan/Amlodipine (Aprovasc) or on lower starting dose should be considered.
Fetal/Neonatal Morbidity and Mortality: Although there is no experience with irbesartan in pregnant women, in utero exposure to ACE inhibitors given to pregnant women during the second and third trimesters has been reported to cause injury and death to the developing fetus. Thus, as for any drug that also acts directly on the renin-angiotensin-aldosterone system, Irbesartan/Amlodipine (Aprovasc) should not be used during pregnancy. If pregnancy is detected during therapy, Irbesartan/Amlodipine (Aprovasc) should be discontinued as soon as possible.
Patients with Heart Failure: In a long-term, placebo controlled study (PRAISE-2) of amlodipine in patients with NYHA III and IV heart failure of non-ischemic etiology, amlodipine was associated with increased reports of pulmonary edema despite no significant difference in the incidence of worsening heart failure as compared to placebo (See Pharmacology: Pharmacodynamics under Actions).
Hepatic impairment: As with all calcium antagonists, the half-life of amlodipine is prolonged in patients with impaired liver function and dosage recommendations have not been established. Irbesartan/Amlodipine (Aprovasc) should therefore be administered with caution in these patients.
Hypertensive crisis: The safety and efficacy of Irbesartan/Amlodipine (Aprovasc) in hypertensive crisis has not been established.
Special Precautions
Dual Blockade of the Renin Angiotensin-Aldosterone System (RAAS): Dual blockade of the RMS by combining Irbesartan/Amlodipine (Aprovasc) with an angiotensin-converting enzyme inhibitor (ACEI) a with aliskiren is not recommended since there are increased risks of hypotension, hyperkalemia, and changes in renal function.
The use of Irbesartan/Amlodipine (Aprovasc) in combination with aliskiren is contraindicated in patients with diabetes mellitus or with renal impairment (GFR <60 mL/min/1.73 m2).
The use of Irbesartan/Amlodipine (Aprovasc) in combination with an ACEI is contraindicated in patients with diabetic nephropathy (See Contraindications and Interactions).
General: As a consequence of inhibiting the renin-angiotensin aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system (e.g., hypertensive patients with renal artery stenosis in one or both kidneys, or patients with severe congestive heart failure), treatment with drugs that affect this system has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. The possibility of a similar effect occurring with the use of an angiotensin II receptor antagonist, including irbesartan, cannot be excluded.
Driving a Vehicle or Performing Other Hazardous Tasks: The effect of IrbesarianfAmlodipine (Aprovasc) on the ability to drive and use machines has not been studied. but based on its pharmacodynamic properties, irbesartan and amlodipine are unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that occasionally dizziness or weariness may occur during treatment of hypertension.
Use In Pregnancy & Lactation
Pregnancy: There are no adequate and well-controlled studies in pregnant women. Irbesartan/Amlodipine (Aprovasc) is contraindicated during pregnancy. Irbesartan/Amlodipine(Aprovasc) must not be administered to women of childbearing potential unless effective contraception is used. When pregnancy is detected, Irbesartan/Amlodipine (Aprovasc) shall be discontinued as soon as possible. (See Contraindications and Warnings).
Lactation: Irbesartan/Amlodipine (Aprovasc) is contraindicated during lactation (See Contraindications).
Drug Interactions
For Irbesartan and Amlodipine: Based on a pharmacokinetic study where irbesartan and amlodipine were given alone or in combination, there is no pharmacokinetic interaction between irbesartan and amlodipine.
No drug interaction studies have been performed with Irbesartan/Amlodipine (Aprovasc) and other medicinal products.
For Irbesartan: Based on in vitro data, no interactions would be expected to occur when irbesartan is co-administered with drugs primarily metabolized by CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1 or CYP3A4.
Irbesartan is primarily metabolized by CYP2C9, however, during clinical interaction studies no significant pharmacodynamic interactions were observed when irbesartan was co-administered with warfarin (metabolized by CYP2C9).
Irbesartan does not affect the pharmacokinetics of simvastatin (metabolized by CYP3A4) or digoxin (substrate of P-glycoprotein efflux transporter).
The pharmacokinetic parameters of irbesartan are not affected by the co-administration with nifedipine or hydrochlorothiazide.
The combination of Irbesartan/Amlodipine (Aprovasc) with aliskiren-containing medicinal products is contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (GFR <60 mL/min/1.73 m2) and is not recommended in other patients.
Angiotensin-convening enzyme inhibitors (ACEIs): The use of Irbesartan/Amlodipine (Aprovasc) in combination with an ACEI is contraindicated in patients with diabetic nephropathy and is not recommended in other patients (see Contraindications and Precautions).
Based on experience with the use of other drugs that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.
In patients who are elderly, volume depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including irbesartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving irbesartan and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including irbesartan, may be attenuated by NSAIDs including selective COX-2 inhibitors.
For Amlodipine: Amlodipine has been safely administered with thiazide diuretics, alpha blockers, beta blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual glyceryl trinitrate, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs.
In vitro data indicate that amlodipine has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin.
Cimetidine: Co-administration of amlodipine with cimetidine did not alter the pharmacokinetics of amlodipine.
Grapefruit juice: Co-administration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine.
Sildenafil: When amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.
Atorvastatin: Co-administration of multiple 10-mg doses of amlodipine with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.
Digoxin: Co-administration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.
Warfarin: Co-administration of amlodipine with warfarin did not change the warfarin prothrombin response time.
Cyclosporine: Pharmacokinetic studies with cyclosporine have demonstrated that amlodipine does not significantly alter the pharmacokinetics of cyclosporine.
Lithium: Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of irbesartan. Monitor lithium levels in patients receiving irbesartan and lithium.
No drug interaction studies have been performed with Irbesartan/Amlodipine (Aprovasc) and other medicinal products.
For Irbesartan: Based on in vitro data, no interactions would be expected to occur when irbesartan is co-administered with drugs primarily metabolized by CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1 or CYP3A4.
Irbesartan is primarily metabolized by CYP2C9, however, during clinical interaction studies no significant pharmacodynamic interactions were observed when irbesartan was co-administered with warfarin (metabolized by CYP2C9).
Irbesartan does not affect the pharmacokinetics of simvastatin (metabolized by CYP3A4) or digoxin (substrate of P-glycoprotein efflux transporter).
The pharmacokinetic parameters of irbesartan are not affected by the co-administration with nifedipine or hydrochlorothiazide.
The combination of Irbesartan/Amlodipine (Aprovasc) with aliskiren-containing medicinal products is contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (GFR <60 mL/min/1.73 m2) and is not recommended in other patients.
Angiotensin-convening enzyme inhibitors (ACEIs): The use of Irbesartan/Amlodipine (Aprovasc) in combination with an ACEI is contraindicated in patients with diabetic nephropathy and is not recommended in other patients (see Contraindications and Precautions).
Based on experience with the use of other drugs that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.
In patients who are elderly, volume depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including irbesartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving irbesartan and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including irbesartan, may be attenuated by NSAIDs including selective COX-2 inhibitors.
For Amlodipine: Amlodipine has been safely administered with thiazide diuretics, alpha blockers, beta blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual glyceryl trinitrate, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs.
In vitro data indicate that amlodipine has no effect on the human plasma protein binding of digoxin, phenytoin, warfarin, and indomethacin.
Cimetidine: Co-administration of amlodipine with cimetidine did not alter the pharmacokinetics of amlodipine.
Grapefruit juice: Co-administration of 240 mL of grapefruit juice with a single oral dose of amlodipine 10 mg in 20 healthy volunteers had no significant effect on the pharmacokinetics of amlodipine.
Sildenafil: When amlodipine and sildenafil were used in combination, each agent independently exerted its own blood pressure lowering effect.
Atorvastatin: Co-administration of multiple 10-mg doses of amlodipine with 80 mg of atorvastatin resulted in no significant change in the steady-state pharmacokinetic parameters of atorvastatin.
Digoxin: Co-administration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.
Warfarin: Co-administration of amlodipine with warfarin did not change the warfarin prothrombin response time.
Cyclosporine: Pharmacokinetic studies with cyclosporine have demonstrated that amlodipine does not significantly alter the pharmacokinetics of cyclosporine.
Lithium: Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of irbesartan. Monitor lithium levels in patients receiving irbesartan and lithium.
Side Effects
Side Effects of AproVasc
Adverse Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
For irbesartan: Irbesartan has beds evaluated for safety in about 5000 subjects in clinical studies. This experience includes 1300 hypertensive patients treated for over 6 months and over 400 patients for 1 year or more. Adverse events generally were mild and transient with no relationship to the dose. The incidence of adverse events was not related to age, gender or race.
In placebo-controlled clinical studies, including 1965 irbesartan-treated patients (usual duration of treatment 1 to 3 months), discontinuations due to any clinical or laboratory adverse events were 3.3% for irbesartan-treated patients and 4.5% for placebo-treated patients (p=0.029). Adverse events that have been reported in irbesartan trials or postmarketing are categorized below according to system organ class and frequency (see Table 3).
The following 00AIS frequency raring is used, when applicable: Very common ≥10%; Common ≥1 and <10%; Uncommon ≥0.1 and <1%; Rare ≥0.01 and <0.1%; Very rare <0.01%, Unknown (cannot be estimated from available data).
Frequencies of adverse reactions from postmarketing experience are unknown, as these reactions are reported voluntarily from a population of uncertain size.
Ingredients
Product Ingredients of AproVasc
Active ingredients: Irbesartan 150mg and Amlodipine 5mg
How to store
How to store AproVasc
Store at temperatures not exceeding 30°C.
Prescription Product
This product requires a prescription from your Doctor.
Please follow the instruction received from the pharmacy on how to forward your prescription to the pharmacy after you have paid for the medicine.
A prescription drug is a pharmaceutical medication that legally requires a medical prescription to be dispensed.
To order this product you confirm that you are under the care of your doctor or consultant and have been given permission by them for purchase, fulfillment & use in treatment with their written consent
Delivery
Delievry time are estimates. Can vary due to the time of day you order.
Delivery time estimate are subject to the courier company.
Shipping to Lagos cost starts from N1850 Next day delivery
Shipping to Rest Of Nigeria – 2-3 days cost starts from N2000
Shipping to Rest of Africa – 5-7 working days Cost starts from N12000
Shipping to Europe 7 – 14 working days Cost srats from N18000
Shipping to Rest of the world – 7 – 14 days Cost starts from N18000
Patient Information Leaflet
You may also like…
Co-Diovan 320/25mg Tablets, 28 Tablets
Original price was: ₦20,000.00.₦16,800.00Current price is: ₦16,800.00.Aprovel 300mg Tablets – Irbesartan 300mg, 28 Tablets
Original price was: ₦9,200.00.₦9,050.00Current price is: ₦9,050.00. — or subscribe and save 10%Advantec Tablets 16mg +12.5mg, 28 Tablets
Original price was: ₦8,500.00.₦8,100.00Current price is: ₦8,100.00.
Related Products
Co-Codamol Tablets, 32 Tablets
₦7,500.00Ketonal Forte 100MG
₦1,300.00Dolo-Meta B Tablets
Original price was: ₦1,000.00.₦900.00Current price is: ₦900.00.
